Fethiann continues to expand its international footprint with high-profile appearances at the Taiwan Expo in Malaysia and Thailand LAB INTERNATIONAL 2025. By showcasing our proprietary FLC (Maqaw) and FMO (Michelia) Botanical New Drug APIs, we are establishing a new benchmark for high-performance, nature-derived medical ingredients.

Strategic Alignment: Supporting Thailand’s BCG Model & Medical Hub Vision

In light of the Thai government’s focus on the “Bio-Circular-Green (BCG)” economy and its ambition to become the “Medical Hub of Asia,” Fethiann offers critical solutions:

• Addressing the API Supply Gap: With 90% of pharmaceutical ingredients in Thailand currently imported, Fethiann’s scientifically validated APIs provide a premium, reliable alternative for local drug manufacturers.
• Driving High-Value Growth: As the BCG sector is projected to account for 25% of Thailand’s GDP by 2025, Fethiann’s commitment to biotechnology and healthcare perfectly aligns with regional industrial upgrades.
• From Nature to Therapy: Our FLC Maqaw extract (targeting joint repair and gout) and FMO Michelia extract (addressing eye fatigue) exemplify our ability to transform native flora into world-class biomedical applications.